Portal de Periódicos da CAPES

Treatment of central precocious puberty with depot leuprorelin

1995; Oxford University Press; Volume: 132; Issue: 6 Linguagem: Inglês

10.1530/eje.0.1320699

1479-683X

Jean‐Claude Carel, Najiba Lahlou, Laura Guazzarotti, M. Joubert-Collin, Marc Roger, Michel Colle, _ _, J L Chaussain,

Hypothalamic control of reproductive hormones

Carel J-C, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M. Colle M, The French Leuprorelin Trial Group, Chaussain JL. Treatment of central precocious puberty with depot leuprorelin. Eur J Endocrinol 1995;132:699–704. ISSN 0804–4643 We evaluated the pituitary and gonadal suppression in 40 girls and nine boys treated with depot leuprorelin (3.75 mg sc if body weight ≥20kg, 1.87 mg if body weight <20 kg) every 28 days for central precocious puberty. Gonadal suppression was obtained in most of the children with this dose: 3 months after initiation of the treatment, 85% of children had a peak plasma luteinizing hormone response to gonadotropin-releasing hormone <3 IU/l and the gonadal axis remained suppressed throughout the duration of the study (up to 24 months). Four patients required higher doses of leuprorelin to achieve suppression. In two girls, a cutaneous reaction to the drug was associated with incomplete suppression and the treatment had to be interrupted. Plasma leuprorelin levels tended to increase from day 3 to day 28 after injection. Residual leuprorelin levels measured 28 days after injection were stable during the first year of the study. We conclude that an initial dose of depot leuprorelin of 3.75 mg sc every 28 days is efficient in most children with central precocious puberty. Jean-Claude Carel, INSERM U342, Hôpital Saint Vincent de Paul, 82 av Denfert Rochereau, 75014 Paris, France